Sulfonylurea therapy benefits neurological and psychomotor functions in patients with neonatal diabetes owing to potassium channel mutations

Diabetes Care

Volumn 38, Issue 11, 2015, Pages 2033-2041

  Beltrand, Jacques ^a,b,c,d   Elie, Caroline ^e   Busiah, Kanetee ^a,b,c,d   Fournier, Emmanuel ^f,g   Boddaert, Nathalie ^a,b,d   Bahi Buisson, Nadia ^a,b,d   Vera, Miriam ^a   Bui Quoc, Emmanuel ^h   Ingster Moati, Isabelle ^a,i   Berdugo, Marianne ^b,j   Simon, Albane ^a,k   Gozalo, Claire ^l   Djerada, Zoubir ^l   Flechtner, Isabelle ^a   Treluyer, Jean Marc ^e   Scharfmann, Raphael ^c   Cavé, Helene ^f,i   Vaivre Douret, Laurence ^a,b,d,f   Polak, Michel ^a,b,c,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b Inserm U1163   (France)

^c INSTITUT COCHIN   (France)

^d IMAGINE INSTITUTE   (France)

^e UNIVERSITÉ DE PARIS   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ Universite Sorbonne Paris Cite   (France)

^j CENTRE DE RECHERCHE DES CORDELIERS   (France)

^k CENTRE HOSPITALIER DE VERSAILLES   (France)

^l HÔPITAL MAISON BLANCHE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; POTASSIUM CHANNEL; ABCC8 PROTEIN, HUMAN; ANTIDIABETIC AGENT; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; SULFONYLUREA RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DEVELOPMENTAL COORDINATION DISORDER; DEVELOPMENTAL SCREENING; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EVOKED VISUAL RESPONSE; FEMALE; FINE MOTOR SKILL; GENE MUTATION; GROSS MOTOR SKILL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERACTIVITY; INFANT; MALE; METABOLIC REGULATION; MOTOR PERFORMANCE; MUSCLE HYPOTONIA; NEONATAL DIABETES MELLITUS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; PSYCHOMOTOR PERFORMANCE; REMISSION; TREATMENT DURATION; WHITE MATTER LESION; YOUNG ADULT; BRAIN; GENETICS; MUTATION; NEUROPSYCHOLOGICAL TEST; NEWBORN; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

ADMINISTRATION, ORAL; ADOLESCENT; BRAIN; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS; DRUG SUBSTITUTION; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT; INFANT, NEWBORN; INSULIN; MAGNETIC RESONANCE IMAGING; MALE; MUTATION; NEUROLOGIC MANIFESTATIONS; NEUROPSYCHOLOGICAL TESTS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PSYCHOMOTOR PERFORMANCE; SULFONYLUREA RECEPTORS;

EID: 84962360295     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0837     Document Type: Article

References (37)

1. Iafusco D, Massa O, Pasquino B, et al.; Early Diabetes Study Group of ISPED.Minimal incidence of neonatal/infancy onset diabetes in Italy is 1: 90, 000 live births. Acta Diabetol 2012;49:405-408.
2. Slingerland AS, Shields BM, Flanagan SE, et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260, 000 live births. Diabetologia 2009;52:1683-1685.
3. Busiah K, Drunat S, Vaivre-Douret L, et al.; French NDM study group. Neuropsychological dysfunction and developmental defects associated with genetic changes in infants with neonatal diabetes mellitus: A prospective cohort study [corrected]. Lancet Diabetes Endocrinol 2013;1:199-207.
4. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATPsensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849.
5. Babenko AP, Polak M, Cavé H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466.
6. Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching frominsulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477.
7. Slingerland AS, Hurkx W, Noordam K, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med 2008;25:277-281.
8. Li B, Xi X, Roane DS, Ryan DH, Martin RJ. Distribution of glucokinase, glucose transporter GLUT2, sulfonylurea receptor-1, glucagon-like peptide-1 receptor and neuropeptide Y messenger RNAs in rat brain by quantitative real time RTPCR. Brain Res Mol Brain Res 2003;113:139-142.
9. Thomzig A, Laube G, Prüss H, Veh RW. Poreforming subunits of K-ATP channels, Kir6.1 and Kir6.2, display prominent differences in regional and cellular distribution in the rat brain. J Comp Neurol 2005;484:313-330.
10. Mlynarski W, Tarasov AI, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol 2007;3:640-645.
11. Vaivre-Douret L. Batterie d'évaluation des fonctions neuro-psychomotrices (NP-MOT) de l'enfant. Paris, France, Editions du Centre de Psychologie Appliqueé, 2006 [in French].
12. Vaivre-Douret L. A more robust predictor of ideomotor dyspraxia: study on an alternative scoringmethod of the Bergès-Lézine's Imitation of Gestures test. Arch Clin Neuropsychol 2002;17:37-48.
13. Vaivre-Douret L. Evaluation of the Distal Motricity Control, Revision and Adaptation Bergés-Lézine's Test. Paris, France, Editions du Centre de Psychologie Appliqueé, 1997 [in French].
14. Bruininks H. Bruininsks-Oserestky Test of Motor Proficiency. Circles Pines, MN, American Guidance Service, 1978.
15. Vaivre-Douret L. Developmental and cognitive characteristics of "high-level potentialities" (highly gifted) children. Int J Pediatr 2011;2011:420297.
16. Vaivre-Douret L, Lalanne C, Ingster-Moati I, et al. Subtypes of developmental coordination disorder: research on their nature and etiology. Dev Neuropsychol 2011;36:614-643.
17. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. San Antonio, TX, The Psychological Corporation, 1989.
18. Wechsler D. Manual for the Wechsler Preschool and Primary Scale of Intelligence-Revised. San Antonio, TX, The Psychological Corporation, 1989.
19. Khos C. Test des Cubes de Khos. Paris, France, Editions du Centre de Psychologie Appliqueé, 1972 in French].
20. Rey A. Manuel test de copie d'une figure complexe. Paris, France, Editions du Centre de Psychologie Appliqueé, 1959 in French].
21. Beery KE. Revised Administration Scoring and Teaching Manual for the Development Test of Visual-Motor Integration (VMI). Toronto, ON, Canada, Modern Curriculum Press, 1982.
22. Jaquier-Roux M, Valdois S, Zorman M, et al. ODEDYS Outil de dépistage des dyslexies, version 2, Cogni-Sciences, IUFM, Paris, France, 2005 [in French].
23. Porteus SD. Test des Labyrinthes de Porteus. Paris, France, Editions du Centre de Psychologie Appliqueé, 1952 in French].
24. Korkman MKU. Developmental Neuropsychological AssessmentManual. Paris, France, Editions du Centre de Psychologie Appliqueé, 2003.
25. Rey A. L'examen psychologique dans le cas d'encéphalopathie traumatique. Arch Psychol 1941;112:286-340 [in French].
26. Odom JV, Bach M, Brigell M, et al. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010;120:111-119.
27. Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M; International Society for Clinical Electrophysiology of Vision. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009;118: 69-77.
28. Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol 2004;56:650-661.
29. Hoizey G, Lamiable D, Trenque T, et al. Identification and quantification of 8 sulfonylureas with clinical toxicology interest by liquid chromatography- ion-trap tandem mass spectrometry and library searching. Clin Chem 2005;51:1666-1672.
30. Slingerland AS, Nuboer R, Hadders-Algra M, Hattersley AT, Bruining GJ. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia 2006;49:2559-2563.
31. Shah RP, Spruyt K, Kragie BC, Greeley SA, Msall ME. Visuomotor performance in KCNJ11-related neonatal diabetes is impaired in children with DEND-associated mutations and may be improved by early treatment with sulfonylureas. Diabetes Care 2012;35:2086-2088.
32. Bendahhou S, Fournier E, Sternberg D, et al. In vivo and in vitro functional characterization of Andersen's syndrome mutations. J Physiol 2005; 565:731-741.
33. Clark RH, McTaggart JS, Webster R, et al. Muscle dysfunction caused by a KATP channel mutation in neonatal diabetes is neuronal in origin. Science 2010;329:458-461.
34. Barnea-Goraly N, Raman M, Mazaika P, et al.; Diabetes Research in Children Network (DirecNet). Alterations in white matter structure in young children with type 1 diabetes. Diabetes Care 2014;37:332-340.
35. Marzelli MJ, Mazaika PK, Barnea-Goraly N, et al.; Diabetes Research in Children Network (DirecNet). Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes 2014;63:343-353.
36. Kunte H, Schmidt S, Eliasziw M, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke 2007;38:2526-2530.
37. Simard JM, Yurovsky V, Tsymbalyuk N, Melnichenko L, Ivanova S, Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009;40:604-609.